Bank of America Securities Reiterates Buy Rating for Novo Nordisk with DKK550 Price Target
ByAinvest
Monday, Jul 7, 2025 8:56 am ET1min read
BAC--
Bank of America Securities analyst Sachin Jain maintained a Buy rating for Novo Nordisk (NVO) on July 1, with a price target of DKK550.00. The company's shares closed at DKK444.71 on the previous day. This rating aligns with the broader analyst consensus, which is a Moderate Buy, with an average price target of DKK629.17, representing a 41.48% upside [3].
Novo Nordisk, a Danish pharmaceutical company with a market cap of DKK1943.9 billion, operates in two primary business segments: Diabetes and Obesity Care, and Rare Disease. The company reported a consolidated turnover of approximately $44 billion on a TTM basis [4]. The company's current P/E ratio is 18.61, indicating its valuation relative to earnings [3].
The analyst consensus on Novo Nordisk is a Moderate Buy, with a price target of DKK629.17, indicating a significant upside potential. UBS also maintained a Buy rating on the stock with a DKK700.00 price target [3]. Despite the positive analyst ratings, corporate insider sentiment has been negative, with 31 insiders selling their shares in the past quarter [3].
Novo Nordisk has been in the news recently for its plans to upgrade its factory in Anagni, Italy, with a planned investment of €2 billion ($2.34 billion). The Italian government has designated the project as being of "pre-eminent strategic interest," allowing for fast-tracking of approval procedures [2].
References:
[1] https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/consensus/
[2] https://www.investing.com/news/stock-market-news/italy-appoints-commissioner-to-accelerate-novo-nordisk-factory-investment-93CH-4124747
[3] https://www.theglobeandmail.com/investing/markets/stocks/NVO/pressreleases/33238912/bank-of-america-securities-sticks-to-its-buy-rating-for-novo-nordisk-0qiu/
[4] https://seekingalpha.com/article/4799487-novo-nordisks-sell-off-has-gone-too-far?source=affiliate_program:stockanalysis.com&utm_medium=affiliate&utm_source=stockanalysis.com&affid=858&oid=16&transaction=2c281206c3a94273909240dabb97b22f
NVO--
UBS--
Bank of America Securities analyst Sachin Jain maintained a Buy rating and DKK550 price target for Novo Nordisk. The analyst consensus is a Moderate Buy with an average price target of DKK629.17, representing a 41.48% upside. Novo Nordisk's market cap is DKK1943.9B and has a P/E ratio of 18.61. Corporate insider sentiment is negative, with 31 insiders selling their shares in the past quarter.
July 02, 2025Bank of America Securities analyst Sachin Jain maintained a Buy rating for Novo Nordisk (NVO) on July 1, with a price target of DKK550.00. The company's shares closed at DKK444.71 on the previous day. This rating aligns with the broader analyst consensus, which is a Moderate Buy, with an average price target of DKK629.17, representing a 41.48% upside [3].
Novo Nordisk, a Danish pharmaceutical company with a market cap of DKK1943.9 billion, operates in two primary business segments: Diabetes and Obesity Care, and Rare Disease. The company reported a consolidated turnover of approximately $44 billion on a TTM basis [4]. The company's current P/E ratio is 18.61, indicating its valuation relative to earnings [3].
The analyst consensus on Novo Nordisk is a Moderate Buy, with a price target of DKK629.17, indicating a significant upside potential. UBS also maintained a Buy rating on the stock with a DKK700.00 price target [3]. Despite the positive analyst ratings, corporate insider sentiment has been negative, with 31 insiders selling their shares in the past quarter [3].
Novo Nordisk has been in the news recently for its plans to upgrade its factory in Anagni, Italy, with a planned investment of €2 billion ($2.34 billion). The Italian government has designated the project as being of "pre-eminent strategic interest," allowing for fast-tracking of approval procedures [2].
References:
[1] https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/consensus/
[2] https://www.investing.com/news/stock-market-news/italy-appoints-commissioner-to-accelerate-novo-nordisk-factory-investment-93CH-4124747
[3] https://www.theglobeandmail.com/investing/markets/stocks/NVO/pressreleases/33238912/bank-of-america-securities-sticks-to-its-buy-rating-for-novo-nordisk-0qiu/
[4] https://seekingalpha.com/article/4799487-novo-nordisks-sell-off-has-gone-too-far?source=affiliate_program:stockanalysis.com&utm_medium=affiliate&utm_source=stockanalysis.com&affid=858&oid=16&transaction=2c281206c3a94273909240dabb97b22f

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet